-

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:

  • BTIG Virtual Biotechnology Conference, presentation at 12:00 p.m. ET on Monday, August 9
  • 2021 Wedbush PacGrow Healthcare Virtual Conference, panel: So Let it Be (Re)Written - Updates in Gene Modulation at 9:10 a.m. ET on Tuesday, August 10

Additional information can be found on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Contacts

Lyndsey Scull, Director, Corporate Communications
202-213-7086
lscull@magentatx.com

Industry:

Magenta Therapeutics, Inc.

NASDAQ:MGTA
Release Versions
English

Contacts

Lyndsey Scull, Director, Corporate Communications
202-213-7086
lscull@magentatx.com

More News From Magenta Therapeutics, Inc.

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today reported financial results for the first quarter ending March 31, 2022, early clinical observations from its MGTA-117 clinical trial and other recent program highlights. “We are pleased with the progress of our MGTA-117 Phase 1/2 clinical trial. Our clinical observations from...

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced progress and encouraging early data in its MGTA-117 Phase 1/2 targeted conditioning clinical trial and a prioritization of its operating plan to more narrowly focus its capital allocation on the MGTA-117 targeted conditioning program, the CD45-ADC (antibody-drug con...

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today reported financial results for the fourth quarter and full-year ended December 31, 2021, and recent program highlights. “We expect 2022 will be a year of trial execution and value-creating data readouts, and we are particularly pleased to have dosed our first patient in the...
Back to Newsroom